Zenas BioPharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Zenas BioPharma, Inc. (ZBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-13
- Zenas BioPharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $978.00K, a 0.20% increase year-over-year.
- Zenas BioPharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $226.00K, a 66.18% increase year-over-year.
- Zenas BioPharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $619.00K.
- Zenas BioPharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $976.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month |
|---|---|---|---|
| 2026-06-30 | $978.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.20M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $226.00K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $619.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.59M derived: sum of 2 quarters · filed 2025-11-12 | $1.73M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $976.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.11M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $136.00K 10-Q · filed 2025-05-15 |